National Center for Geriatrics and Gerontology

Yuji Yoshiike

The present invention provides a tau protein aggregation inhibitor. In addition, a therapeutic agent or a preventive agent for tauopathy, including a tau protein aggregation inhibitor, and a method for screening for a tau protein aggregation inhibitor, are also provided. The problems are solved by a tau protein aggregation inhibitor including a fluorone dye or a pharmaceutically acceptable salt thereof. Moreover, the problems are also solved by a method for screening a tau protein aggregation inhibitor, wherein the method includes: (1) a step of preparing transgenicthat express a human tau protein in neurons, (2) a step of administering a candidate compound to the transgenic, and (3) a step of measuring the motor function of the transgenicthat have been administered with the candidate compound in the step (2).

Growing community of inventors

Obu, Japan

Yuji Yoshiike